Page last updated: 2024-12-07

lavendamycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Lavendamycin is a natural product antibiotic produced by Streptomyces lavendulae. It exhibits potent antitumor activity, particularly against leukemia cells, and has been studied for its potential as a chemotherapeutic agent. Its mechanism of action involves DNA intercalation, inhibiting DNA replication and transcription. Lavendamycin is a complex molecule with a unique structure containing a quinoline ring system and a cyclopropyl group. Its synthesis has been a challenging undertaking due to the presence of multiple chiral centers. Several research groups have investigated its synthesis, with various strategies employed to achieve its preparation. However, its clinical application has been limited by its toxicity and the development of resistance. Ongoing research focuses on understanding its mechanism of action and developing analogs with improved therapeutic profiles.'

lavendamycin: from Streptomyces lavendulae; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID100585
MeSH IDM0106488

Synonyms (14)

Synonym
nsc322370
nsc-322370
81645-09-2
lavendamycin
1-(7-amino-5,8-dioxoquinolin-2-yl)-4-methyl-9h-pyrido[3,4-b]indole-3-carboxylic acid
nsc 322370
unii-xl8988yp79
xl8988yp79 ,
9h-pyrido(3,4-b)indole-3-carboxylic acid, 1-(7-amino-5,8-dihydro-5,8-dioxo-2-quinolinyl)-4-methyl-
1-(7-amino-5,8-dihydro-5,8-dioxo-2-quinolinyl)-4-methyl-9h-pyrido(3,4-b)indole-3-carboxylic acid
Q1808882
1-(7-amino-5,8-dioxo-5,8-dihydroquinolin-2-yl)-4-methyl-9h-pyrido[3,4-b]indole-3-carboxylic acid
DTXSID401002112
AKOS040747018

Research Excerpts

Overview

Lavendamycin is a bacterially derived quinolinedione that displays significant antimicrobial and antitumor activities.

ExcerptReferenceRelevance
"Lavendamycin is a bacterially derived quinolinedione that displays significant antimicrobial and antitumor activities. "( Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin.
Abraham, RT; Behforouz, M; Cai, W; Fang, Y; Linardic, CM; Richardson, DA, 2003
)
1.98

Toxicity

ExcerptReferenceRelevance
" The best substrates for NQO1 were also the most selectively toxic to the NQO1-rich BE-NQ cells compared to NQO1-deficient BE-WT cells with 37 as the most selective."( Novel lavendamycin analogues as antitumor agents: synthesis, in vitro cytotoxicity, structure-metabolism, and computational molecular modeling studies with NAD(P)H:quinone oxidoreductase 1.
Beall, HD; Behforouz, M; Cai, W; Ebrahimian, GR; Gerdes, JM; Hassani, M; Holley, DC; Lineswala, JP; Maharjan, BR; Marvin, CC; Mohammadi, F; Seradj, H; Stocksdale, MG, 2005
)
0.81
" Metabolism and toxicity studies demonstrated that the best substrates for NQO1 were also the most selectively toxic to NQO1-rich tumor cells compared to NQO1-deficient tumor cells."( Synthesis, metabolism and in vitro cytotoxicity studies on novel lavendamycin antitumor agents.
Beall, HD; Behforouz, M; Cai, W; Charkhzarrin, S; Eads, TJ; Hassani, M; Hermann, NG; Karki, R; Koelsch, KH; Lineswala, JP; Lucas, JS; Mirzaei, H; Olang, F; Rose, AS; Sedighi, M; Seradj, H; Walter, ED; York, JS, 2010
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (18.75)18.7374
1990's2 (12.50)18.2507
2000's8 (50.00)29.6817
2010's3 (18.75)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.64 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]